Investigational Drug Information for IMG-7289

What is the drug development status for IMG-7289?

IMG-7289 is an investigational drug.

There have been 12 clinical trials for IMG-7289. The most recent clinical trial was a Phase 1 trial, which was initiated on May 23^rd 2024.

The most common disease conditions in clinical trials are Thrombocythemia, Essential, Thrombocytosis, and Primary Myelofibrosis. The leading clinical trial sponsors are Imago BioSciences,Inc., Terrence J Bradley, MD, and Merck Sharp & Dohme LLC.

There are sixty-eight US patents protecting this investigational drug and one hundred and sixty-eight international patents.

Summary for IMG-7289

US Patents	68
International Patents	168
US Patent Applications	199
WIPO Patent Applications	71
Japanese Patent Applications	10
Clinical Trial Progress	Phase 1 (2024-05-23)
Vendors	22

Recent Clinical Trials for IMG-7289

Title	Sponsor	Phase
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)	Merck Sharp & Dohme LLC	PHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)	Merck Sharp & Dohme LLC	Phase 3
Bomedemstat in Patients With Polycythemia Vera	Imago BioSciences,Inc.	Phase 2

See all IMG-7289 clinical trials

Clinical Trial Summary for IMG-7289

Top disease conditions for IMG-7289

Top clinical trial sponsors for IMG-7289

See all IMG-7289 clinical trials

US Patents for IMG-7289

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
IMG-7289		Chemokine receptor modulators and uses thereof	FLX Bio, Inc. (South San Francisco, CA)
IMG-7289		Chemokine receptor modulators and uses thereof	FLX BIO, INC. (South San Francisco, CA)
IMG-7289		Tank-binding kinase inhibitor compounds	Gilead Sciences, Inc. (Foster City, CA)
IMG-7289		Antiproliferative compounds and methods of use thereof	Celgene Corporation (Summit, NJ)
IMG-7289		KDM1A inhibitors for the treatment of disease	Imago Biosciences Inc
IMG-7289		Chemokine receptor modulators and uses thereof	RAPT THERAPEUTICS, INC. (South San Francisco, CA)
IMG-7289		Antiproliferative compounds and methods of use thereof	Celgene Corporation (Summit, NJ)

International Patents for IMG-7289

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
IMG-7289	Australia	AU2017302635	2036-07-29
IMG-7289	Brazil	BR112019001732	2036-07-29
IMG-7289	Canada	CA3032133	2036-07-29
IMG-7289	China	CN109789146	2036-07-29
IMG-7289	Denmark	DK3490565	2036-07-29
IMG-7289	European Patent Office	EP3490565	2036-07-29
IMG-7289	Spain	ES2925564	2036-07-29

IMG-7289 Market Analysis and Financial Projection

Last updated: April 25, 2026

IMG-7289: Development Update and Market Projection

No development update or market projection can be produced for IMG-7289 based on the information available in this chat.

What is IMG-7289’s current development status?

No status (preclinical, Phase 1/2/3), trial identifiers, sponsor, enrollment milestones, primary endpoints, or reported safety/efficacy data are provided here. Without those inputs, a complete and accurate development update cannot be assembled.

What market projection can be quantified?

No indication (oncology, immunology, infectious disease, etc.), target biology, mechanism of action, patient population size, pricing assumptions, competitive set, geography, forecast horizon, or reimbursement constraints are provided here. Without those inputs, a quantified market projection cannot be produced.

What can be stated from patent and regulatory anchors?

No regulatory identifiers (IND/NDA/BLA), no applicant names, no jurisdictional filings, no priority dates, and no patent numbers are provided here. Without those anchors, a defensible market projection and investment-grade development view cannot be constructed.

---

Key Takeaways

• IMG-7289 cannot be placed into a verified development stage or timeline from the information provided.
• A quantified market projection requires indication, competitive landscape, geography, and pricing/reimbursement assumptions that are not available here.
• No patent, regulatory, or clinical identifiers are present to ground either forecast or development milestones.

---

FAQs

1. Is there enough data here to summarize IMG-7289 clinical progress?
   No. No trial phase, study IDs, endpoints, or results are provided.

2. Can a revenue forecast be calculated for IMG-7289 from this chat?
   No. Indication, patient population, pricing, and competition inputs are not provided.

3. Can regulatory status be confirmed (IND, Phase 1, etc.)?
   No. No regulatory identifiers or filings are provided.

4. Can the competitive set be defined for IMG-7289?
   No. The target indication and mechanism are not provided.

5. Can patent coverage be assessed for IMG-7289?
   No. No patent numbers, assignees, or priority data are provided.

---

References

No sources cited.